Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11-valent recombinant human papillomavirus vaccine (Hansenula polymorpha)
- Development stage
- Unknown
- Lead developer
- National Vaccine and Serum Institute
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 11-valent recombinant human papillomavirus (HPV) vaccine is a multi-valent biologic vaccine developed by the National Vaccine and Serum Institute (NVSI) of China, a subsidiary of China National Biotec Group (CNBG). Produced using a *Hansenula polymorpha* yeast expression system, the vaccine contains recombinant virus-like particles (VLPs) representing 11 different HPV types. It is designed to elicit a protective immune response to prevent HPV infection and associated malignancies, specifically cervical cancer. The vaccine is currently in Phase III clinical development in China, evaluated in a three-dose intramuscular regimen for women aged 18 to 45. It represents an expansion in coverage over existing 9-valent vaccines by targeting additional high-risk HPV types.
- Other names
- 11-valent HPV vaccine11-valent recombinant HPV vaccine11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
02
Targets
HPV L1 (Human papillomavirus L1 capsid protein)
Beyond the preview
Go deeper on 11-valent recombinant human papillomavirus vaccine (Hansenula polymorpha).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11-valent recombinant human papillomavirus vaccine (Hansenula polymorpha).